Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Fumarate hydratase inactivation in hereditary leiomyomatosis and renal cell cancer is synthetic lethal with ferroptosis induction

19 Jun 2018

Abstract excerpt

Hereditary leiomyomatosis and renal cell cancer (HLRCC) is a hereditary cancer syndrome characterized by inactivation of the Krebs cycle enzyme fumarate hydratase (FH). HLRCC patients are at high risk of developing kidney cancer of type 2 papillary morphology that is refractory to current radiotherapy, immunotherapy and chemotherapy. Hence, an effective therapy for this deadly form of cancer is urgently needed....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer-related gene regulation
Share to Renal and related cancers
Share to Renal cell carcinoma treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 29917289
DOI: 10.1111/cas.13701

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Fumarate hydratase inactivation in hereditary leiomyomatosis and renal cell cancer is synthetic lethal with ferroptosis inductionPMID 29917289Read ↗

Advances in hereditary leiomyomatosis and renal cell carcinoma (HLRCC) research.Semantic proximity Read ↗

Fumarate hydratase as a therapeutic target in renal cancerSemantic proximity Read ↗

FH variant pathogenicity promotes purine salvage pathway dependence in kidney cancerSemantic proximity Read ↗

Novel morphological and genetic features of fumarate hydratase deficient renal cell carcinoma in HLRCC syndrome patients with a tailored therapeutic approachSemantic proximity Read ↗

Targeting strategies in the treatment of fumarate hydratase deficient renal cell carcinomaSemantic proximity Read ↗

Fumarate hydratase-deficient renal cell carcinoma: a single institution-based study of 29 patients by clinicopathological, immunohistochemical and genetic approachesSemantic proximity Read ↗

Rare insights into cancer biology.Semantic proximity Read ↗

Comprehensive Molecular Characterization and Response to Therapy in Fumarate Hydratase-Deficient Renal Cell Carcinoma.Semantic proximity Read ↗

Conditional covalent lethality driven by oncometabolite accumulationSemantic proximity Read ↗

FH Variant Pathogenicity Promotes Purine Salvage Pathway Dependence in Kidney CancerSemantic proximity Read ↗

Proteogenomic landscape of uterine leiomyomas from hereditary leiomyomatosis and renal cell cancer patients.Semantic proximity Read ↗

Pathological Oxidation of PTPN12 Underlies ABL1 Phosphorylation in HLRCCSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.